

CERTIFICATE OF MAILING

I hereby certify that this Supplemental IDS and recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on Light 11, 2002.

Assistant Commissioner for Patents Washington, DC 20231

April 11, 2002

04/17/2002 DTESSEM1 00000063 191025 09731349 01 FC:126 180.00 CH

Sir:

DATE:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement (IDS) is filed in accordance with the duty of disclosure under 37 C.F.R. § 1.56 and §§ 1.97-1.98, as supplemented by M.P.E.P. § 609. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise. This IDS supplements that submitted on October 19, 2001.

This IDS is filed under the provisions of 37 C.F.R. § 1.97(c). Please charge \$180.00 or the sum required under 37 C.F.R. § 1.17(p) to Deposit Account No. 19-1025.

Document B1 is an English language version of an Ecuador application believed by Applicant to have been laid open on May 6, 1999. It contains similar, although not identical, disclosure to International Patent Publication No. WO 00/32189, cited by the Examiner in an Office Action dated December 31, 2001.



Documents B2 and B3 were cited in an International Search Report dated May 17, 2001, in counterpart International Patent Application No. PCT/US00/32433. A copy of that Search Report is also enclosed herewith for the Examiner's convenience.

Document C1 is cited in the present specification at page 2, lines 11-12, and was inadvertently omitted from the IDS submitted on October 19, 2001.

Documents C2–C6 were cited in a third party statement filed in Guatemala against Guatemalan Patent Application No. PI-2000-0207, which is a counterpart of the present application. Of these, document C3 is in the Spanish language and an English language translation is provided for the Examiner's convenience. Applicant does not believe these documents are material to patentability of the present invention, but wishes to bring them before the Examiner for his independent consideration. Documents C2–C6 were apparently adduced as evidence in support of the Guatemala third party statement to the effect that valdecoxib was in Phase III development and that submission to the U.S. FDA had been made for registration of valdecoxib, as of the date of the statement (December 14, 2001).

Respectfully submitted,

lames C tobbes

James C. Forbes

Agent for Applicant

Registration No. 39,457

Tel. 847-581-6090

Address correspondence to:

Pharmacia Corporation
Patent Department – O4B
800 N Lindbergh Boulevard
St Louis, MO 63167

Enclosures:

International Search Report, PCT/US00/32433 Form PTO-1449 Cited art